Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
eNrFWE1z2jAQvfMrGM+kN9vgQCCtTSYloWUmTCmEttMLI+w1iBrJkWQ++usr22RCWnvSCDQ5cEAfb1fap7e7dq+2q6i6BsYxJZ5Rt2pGFYhPA0zmnjG575lt46pTcZdojQ6WyXWW4xhVP0Kce0Y6a80AEW79GNzdgNwPzOhUqi6dLcEXz9YlAkfWZ8QXAxSna6rumuKgugKxoIFnxInIRqsuF0x60dlQ9ovHyAfX3o8czi6njcNx107B/gM14cDuEJkXggJRwvQTxoCILhIwp2xX4u+5EjbmI+A0YT4MkVgMGV3jAIJCEyGKOCgZCTfBGNg6ApEaKQS3l/6KK4GjJdqO4KFf7PS1nO2KrTBrZr1Vb7ScdqNVqzWaSqbYwVUVR0Eewvan7YuL1qVjA8lOZYf+1Gm3mtJ+OiRBkkggYQZgMvAXwOTPRETggArTqdUvFQM5pEygSFMIMe8+Z6EmOwweXqRKgHkcoZ215LHqVSGG5DQwqRX6DpKe4J5J9Yrknf2FT5Iosl/p9WSvLZo8TqWrSxMiSiSmN1K9iC4lArblEVVTRbHdcxEDPx3sb0qKM8IwmUXYV9U/qVAJcDEZ9cvl782U4yPiMGH6pOM7JgHd8NNL0iEFNHkfZ6paCBqzoD51LtsX9WZT+cX9lHwryV23CaMx2FKsMD9Gg/okpMeqj6RwMdQjgd+Gu1m5RX0UQUnBNVVULUnax/pQ27PQ9+TyiULQT7f3qlz6mgDbjbO/hdA48B5ZoKboOtKEJO5LfqdGvXdoFX8QqzgrDTyxi4GHZ+c3QnKV0IjOpcKcOb05EGBpNreuv/XHAwiwLwsJIvLd2SbvNVtoPAYkn0JuPtca72hdyXG09AsJK9bChRAxf2/bm83GWiBucvm0wQrZiRLb1VOMjo+TYqz+jdcpYyaz2RP99fVhWkqxvDTNM5km12d5ifI67qkK3UvF2rENyH7/vtEp1iSWwBGxyHOitszVvz19MnzqPrS5PXymi/rMZJ0CEpgSXUVpMitEPCr9yrCSHpP68CUMcclnsVJaunb+Sa5Tce30c1yn8gdGspwa
NEc4CzT6ZUZD89an